FindTrial
Sign In

Preliminary study on the difference of VHL expression between primary and metastatic renal clear cell carcinoma

Preliminary study on the difference of VHL expression between primary and metastatic renal clear cell carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200060727
Enrollment
Unknown
Registered
2022-06-09
Start date
2022-05-30
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal clear cell carcinoma

Interventions

case series:NA

Sponsors

Zhongnan Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Renal clear cell carcinoma was diagnosed by pathology; 2. Imaging examination including PET-CT, CT or MRI is considered as advanced / metastatic clear cell renal carcinoma: T4N0~1M0/T1~4N0~1M1; 3. Primary and metastatic tissues of renal cell carcinoma can be obtained.

Exclusion criteria

Exclusion criteria: 1. Patients with other neoplastic diseases; 2. Renal cell carcinoma with other pathological types besides renal clear cell carcinoma.

Design outcomes

Primary

MeasureTime frame
Overall survival;Progress-free survival;—

Countries

China

Contacts

Public ContactHua Xu

Zhongnan Hospital of Wuhan University

xuhuawhu@163.com+86 13971051016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026